Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Arcturus Therapeutics Holdings Inc.    ARCT

ARCTURUS THERAPEUTICS HOLDINGS INC.

(ARCT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/14/2021 01/15/2021 01/19/2021 01/20/2021 01/21/2021 Date
62.27(c) 59.69(c) 68.45(c) 67.3(c) 64.56 Last
1 917 497 1 611 936 2 485 457 1 873 332 1 338 338 Volume
-4.65% -4.14% +14.68% -1.68% -4.07% Change
More quotes
Financials (USD)
Sales 2020 9,72 M - -
Net income 2020 -63,6 M - -
Net cash position 2020 287 M - -
P/E ratio 2020 -21,8x
Yield 2020 -
Sales 2021 96,0 M - -
Net income 2021 -29,1 M - -
Net Debt 2021 - - -
P/E ratio 2021 -45,4x
Yield 2021 -
Capitalization 1 740 M 1 740 M -
EV / Sales 2020 149x
Capi. / Sales 2021 18,1x
Nbr of Employees 88
Free-Float 81,9%
More Financials
Company
Arcturus Therapeutics Holdings Inc. is a clinical-stage messenger ribonucleic acid (mRNA) medicines and vaccines company. The Company’s technologies include LUNAR lipid-mediated delivery, STARR mRNA Technology and mRNA drug substance along with drug product manufacturing. Its pipeline of ribonucleic acid (RNA) therapeutic candidates include programs to treat ornithine transcarbamylase (OTC) deficiency, cystic... 
More about the company
Notations Surperformance© of Arcturus Therapeutics Holdings Inc.
Trading Rating : Investor Rating :
More Ratings
All news about ARCTURUS THERAPEUTICS HOLDINGS INC.
01/19ARCTURUS THERAPEUTICS : B. Riley Cuts Arcturus Therapeutics Holdings to Neutral ..
MT
01/07ARCTURUS THERAPEUTICS : Wells Fargo Starts Arcturus Therapeutics at Overweight W..
MT
01/06ARCTURUS THERAPEUTICS : to Present at Upcoming Investor Conference
BU
01/04ARCTURUS THERAPEUTICS : Get's FDA Nod for Phase 2 Study of COVID-19 Vaccine Cand..
MT
01/04ARCTURUS THERAPEUTICS : Receives FDA Allowance to Proceed with Phase 2 Study of ..
BU
2020ARCTURUS THERAPEUTICS : Selects ARCT-032 as Development Candidate For Cystic Fib..
MT
2020ARCTURUS THERAPEUTICS : to Advance ARCT-032, an Aerosolized LUNAR® mRNA-based Th..
BU
2020Arcturus, Simon Property fall; Fulgent, Expedia rise
AQ
2020SECTOR UPDATE : Health Care Stocks Ending Higher in Weak Tuesday Market
MT
2020SECTOR UPDATE : Health Care Stocks Resisting Tuesday's Negative Market Tone
MT
2020MIDDAY REPORT : Wall Street Softer Midday, Key Indexes Near Record Levels
MT
2020SECTOR UPDATE : Health Care Stocks Flat to Higher Premarket Tuesday
MT
2020Wall Street Sees Another Round of Gains Amid Stimulus-Led Rally
MT
2020ARCTURUS THERAPEUTICS : Received Approval from Singapore Health Sciences Authori..
AQ
2020ARCTURUS THERAPEUTICS : HC Wainwright Downgrades Arcturus Therapeutics to Neutra..
MT
More news
News in other languages on ARCTURUS THERAPEUTICS HOLDINGS INC.
2020MÄRKTE USA/Nach neuen Rekorden läuft Rally aus
2020MÄRKTE USA/Nach neuen Rekorden schmelzen Gewinne ab
2020MÄRKTE USA/Börsen mit neuen Rekordhochs zu Handelsbeginn
2020WALL STREET STOCK EXCHANGE : Les valeurs à suivre à Wall Street
2020WALL STREET STOCK EXCHANGE : USA-Les valeurs à suivre à Wall Street
More news
Analyst Recommendations on ARCTURUS THERAPEUTICS HOLDINGS INC.
More recommendations
Chart ARCTURUS THERAPEUTICS HOLDINGS INC.
Duration : Period :
Arcturus Therapeutics Holdings Inc. Technical Analysis Chart | ARCT | US03969T1097 | MarketScreener
Technical analysis trends ARCTURUS THERAPEUTICS HOLDINGS INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Average target price 99,42 $
Last Close Price 67,30 $
Spread / Highest target 126%
Spread / Average Target 47,7%
Spread / Lowest Target -31,6%
EPS Revisions
Managers and Directors
NameTitle
Joseph E. Payne President, Chief Executive Officer & Director
Peter C. Farrell Chairman
Padmanabh Chivukula Secretary, Chief Operating & Scientific Officer
Andrew H. Sassine Chief Financial Officer & Director
James F. Barlow Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ARCTURUS THERAPEUTICS HOLDINGS INC.55.14%1 740
MODERNA, INC.19.79%49 519
LONZA GROUP AG4.32%49 499
CELLTRION, INC.-13.09%38 562
IQVIA HOLDINGS INC.6.35%36 531
SEAGEN INC.8.94%34 515